Sanjay Koul

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Characteristic promoter hypermethylation signatures in male germ cell tumors
    Sanjay Koul
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY, 10032, USA
    Mol Cancer 1:8. 2002
  2. ncbi Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors
    Sanjay Koul
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Mol Cancer 3:16. 2004
  3. ncbi Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Oncogene 22:3489-99. 2003
  4. ncbi Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome
    Gopeshwar Narayan
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mol Cancer 2:24. 2003
  5. ncbi Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes
    Veronique Bourdon
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6218-23. 2002

Detail Information

Publications5

  1. ncbi Characteristic promoter hypermethylation signatures in male germ cell tumors
    Sanjay Koul
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY, 10032, USA
    Mol Cancer 1:8. 2002
    ..GCTs exhibit pluripotentiality and are highly sensitive to cisplatin therapy. The molecular basis of germ cell (GC) transformation, differentiation, and exquisite treatment response is poorly understood...
  2. ncbi Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors
    Sanjay Koul
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Mol Cancer 3:16. 2004
    ..Male germ cell tumor (GCT) is a highly curable malignancy, which exhibits exquisite sensitivity to cisplatin treatment. The genetic pathway(s) that determine the chemotherapy sensitivity in GCT remain largely unknown...
  3. ncbi Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Oncogene 22:3489-99. 2003
    ..Thus, these data identify frequent chromosomal amplifications in CC, and sites of TSGs at 2q35-q36.1 and 2q36.3-q37.1 that are critical in CC development...
  4. ncbi Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome
    Gopeshwar Narayan
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mol Cancer 2:24. 2003
    ..Although a host of genetic alterations have been identified, molecular basis of CC development is still poorly understood...
  5. ncbi Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes
    Veronique Bourdon
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6218-23. 2002
    ..Combined array comparative genomic hybridization and array expression analysis is a valid approach for gene discovery in large chromosomal amplicons...